About AMLo Biosciences
AMLo Biosciences is a company based in Newcastle Upon Tyne (United Kingdom) founded in 2017 by Penny Lovat and Marie Labus. It operates as a HealthTech. AMLo Biosciences has raised $7.69 million across 4 funding rounds from investors including Northstar Ventures, Esperante and Ascension. The company has 11 employees as of December 31, 2021. AMLo Biosciences offers products and services including AMBLor, cSCC Prognostic Test, and OPSCC Prognostic Test. AMLo Biosciences operates in a competitive market with competitors including DermTech, Castle Biosciences, Haut, MELAGENIX and Veriskin, among others.
- Headquarter Newcastle Upon Tyne, United Kingdom
- Employees 11 as on 31 Dec, 2021
- Founders Penny Lovat, Marie Labus
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Amlo Biosciences Limited
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$7.69 M (USD)
in 4 rounds
-
Latest Funding Round
$2.01 M (USD), Series A
Nov 27, 2024
-
Investors
Northstar Ventures
& 6 more
-
Employee Count
11
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AMLo Biosciences
AMLo Biosciences offers a comprehensive portfolio of products and services, including AMBLor, cSCC Prognostic Test, and OPSCC Prognostic Test.
AMBLor is developed for melanoma risk stratification purposes.
Test is designed for cutaneous squamous cell carcinoma prognosis.
Test is created for oropharyngeal squamous cell carcinoma prognosis.
People of AMLo Biosciences
Unlock access to complete
Unlock access to complete
Funding Insights of AMLo Biosciences
AMLo Biosciences has successfully raised a total of $7.69M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $2.01 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AMLo Biosciences
AMLo Biosciences has secured backing from 7 investors, including venture fund investors. Prominent investors backing the company include Northstar Ventures, Esperante and Ascension.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments are made in UK companies across diverse sectors.
|
Locked | Locked | Locked | |
|
Esperante is focused on innovative life science investments.
|
Locked | Locked | Locked | |
|
Ascension is recognized as a venture capital firm focused on early-stage tech investments.
|
Locked | Locked | Locked |
Investor details for AMLo Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AMLo Biosciences
Investment portfolio details for AMLo Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AMLo Biosciences
Detailed financials for AMLo Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Amlo Biosciences Comparisons
Peer comparison for AMLo Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AMLo Biosciences
AMLo Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DermTech, Castle Biosciences, Haut, MELAGENIX and Veriskin, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Adhesive patch biopsies for skin cancer detection are provided.
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
SaaS solutions using AI for skincare businesses are provided.
|
|
| Locked | Locked | Locked |
Molecular diagnostic tests for skin cancer detection are developed.
|
|
| Locked | Locked | Locked |
Tools for non-invasive skin cancer diagnosis are developed.
|
Detailed competitors of AMLo Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Amlo Biosciences
Complete news archive for AMLo Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AMLo Biosciences
AMLo Biosciences was founded in 2017 and raised its 1st funding round 1 year after it was founded.
AMLo Biosciences is headquartered in Newcastle Upon Tyne, United Kingdom.
Marie Labus is the current CEO of AMLo Biosciences. They have also founded this company.
AMLo Biosciences is a funded company, having raised a total of $7.69M across 4 funding rounds to date.
As of Dec 31, 2021, the latest employee count at AMLo Biosciences is 11.
AMLo Biosciences is engaged in translating cancer biomarker research into prognostic and diagnostic products. The company targets melanoma, cutaneous squamous cell carcinoma, and oropharyngeal squamous cell carcinoma. Solutions are developed to improve patient outcomes by identifying disease progression risks. Efforts are directed towards reducing financial burdens on global healthcare systems. Products like AMBLor are designed to stratify risk in early-stage melanoma patients. The focus is maintained on optimizing healthcare resources through precise patient management.
AMLo Biosciences's top competitors include DermTech, Castle Biosciences and MELAGENIX.
AMLo Biosciences offers AMBLor, cSCC Prognostic Test, and OPSCC Prognostic Test.
AMLo Biosciences has 7 investors. Key investors include Northstar Ventures, Esperante, Ascension, Conduit Connect, and Future Planet Capital.